Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Supernus Pharmaceuticals (Nasdaq: SUPN) will announce its preliminary financial results for Q4 and full year 2021, along with its guidance for 2022, on February 28, 2022, after market close. A conference call hosted by CEO Jack Khattar and CFO Tim Dec will take place at 4:30 PM ET the same day. Investors can access the live webcast on the company's website. Supernus develops treatments for CNS diseases, with a portfolio covering epilepsy, migraine, and more.
Supernus Pharmaceuticals (Nasdaq: SUPN) has received notice from the FDA regarding its New Drug Application (NDA) resubmission for the apomorphine infusion device (SPN-830) aimed at treating motor fluctuations in Parkinson’s disease. The FDA has classified the review as Standard, with a timeline set for 10 months, leading to a target action date in early October 2022. Supernus plans to prepare for a commercial launch of SPN-830 in Q1 2023, contingent on FDA approval.
Supernus Pharmaceuticals (NASDAQ: SUPN) has resubmitted its New Drug Application (NDA) for the apomorphine infusion device (SPN-830) to treat motor fluctuations in Parkinson’s Disease (PD). This follows a Refusal to File (RTF) letter from the FDA in November 2020, which noted the application was incomplete. The resubmission is significant as SPN-830 could provide a novel treatment option for PD patients, offering a less invasive alternative for managing OFF episodes. The company remains focused on CNS disease treatments, with various approved and developing products in their pipeline.
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) announced it was targeted by a ransomware attack that began around mid-November 2021. The Company reported that the attack had no significant impact on its operations and that no ransom payments were made. Following detection, it engaged cybersecurity experts and successfully recovered the affected files. The Company remains vigilant, monitoring the situation and ensuring the protection of any confidential information. Despite the incident, Supernus continues to operate normally as it develops treatments for CNS diseases.
Supernus Pharmaceuticals has completed its acquisition of Adamas Pharmaceuticals, enhancing its Parkinson’s disease portfolio with GOCOVRI® and Osmolex ER®. The deal diversifies revenue streams, expected to yield synergies of $60M to $80M in the first year, and is projected to be accretive in 2022. Supernus offered $8.10 cash per share of Adamas, totaling about 77.3% tendered shares. Adamas stock will be delisted post-merger. The acquisition aligns with Supernus's strategy to strengthen its CNS product offerings, contributing to cash flow stability.
Supernus Pharmaceuticals (NASDAQ: SUPN) announced that the waiting period under the Hart-Scott-Rodino Act for its proposed acquisition of Adamas Pharmaceuticals (NASDAQ: ADMS) expired on November 22, 2021. The acquisition offer includes $8.10 per share in cash and two contingent value rights (CVRs) worth up to $1.00, dependent on achieving sales milestones by December 2024 and December 2025. The tender offer expires at 11:59 p.m. on November 23, 2021, unless extended. Upon completion, Adamas will become a wholly-owned subsidiary of Supernus.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. Management will hold a fireside chat available from 10:00 a.m. ET on November 22, 2021, with an archived replay accessible for 60 days. Supernus focuses on developing treatments for central nervous system diseases, including epilepsy and Parkinson’s disease. The company will also host investor meetings on December 1, 2021.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced its participation in two investor conferences in November 2021. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 15 at 2:00 p.m. EST, featuring a fireside chat format. The Jefferies London Healthcare Conference will take place on November 18, with a pre-recorded session available from 3:00 a.m. EST / 8:00 a.m. GMT. Live webcasts and archived replays of both chats will be accessible on the company’s website for 60 days post-conference.
Supernus Pharmaceuticals reported a 12% increase in total revenues for the first nine months of 2021, reaching $420.7 million compared to $376.8 million in 2020. However, Q3 revenues decreased by 4% to $148.5 million year-over-year. The company is diversifying its Parkinson's portfolio through the proposed $450 million acquisition of Adamas Pharmaceuticals, aiming to enhance revenue and cash flow. Key product Qelbree saw accelerated growth, with a significant rise in prescriptions. Financial guidance for 2021 reflects an increase in operating earnings, with total revenue expected between $550 million and $570 million.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that it will report its third quarter 2021 financial results on November 3, 2021, after market close. The company's President and CEO, Jack Khattar, along with SVP and CFO Tim Dec, will host a conference call at 4:30 p.m. ET to discuss the results and address questions. A live webcast will be accessible on their website, with a recording available for 60 days thereafter. Supernus specializes in CNS disease treatments, including epilepsy and ADHD, and is developing new potential therapies.